Russia Expects Green Light for mRNA Vaccine to Treat Melanoma in 2026

Moscow — Russia’s first messenger RNA (mRNA) vaccine developed to treat melanoma skin cancer could receive approval for use in humans as early as 2026.

Alexander Gintsburg, head of the Gamaleya National Research Center for Epidemiology and Microbiology, said the center has already produced several pilot batches of the melanoma cancer vaccine at the institute’s dedicated manufacturing facility.

Speaking on Thursday (Dec. 11), Gintsburg said three batches of the vaccine had been manufactured. These batches are not intended for human use, but were produced to test equipment performance and to carry out the required quality control procedures. The checks have now confirmed that the vaccine meets the established standards.

Earlier, Russia’s Ministry of Health approved the mRNA melanoma cancer vaccine, known as Neooncovac, for clinical use. The vaccine was jointly developed by the Gamaleya Center and the Blokhin National Medical Research Center of Oncology, with production overseen by the National Medical Research Center of Radiology.

Source: www.xinhuathai.com